Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada.
Faculty of Science, McMaster University, Hamilton, ON, Canada.
Syst Rev. 2021 Dec 22;10(1):317. doi: 10.1186/s13643-021-01871-7.
In December 2019, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 was identified as the cause of an acute respiratory disease, coronavirus disease 2019 (COVID-19). Given the lack of validated treatments, there is an urgent need for a high-quality management of COVID-19. Clinical practice guidelines (CPGs) are one tool that healthcare providers may use to enhance patient care. As such, it is necessary that they have access to high-quality evidence-based CPGs upon which they may base decisions regarding the management and use of therapeutic interventions (TI) for COVID-19. The purpose of the proposed study is to assess the quality of CPGs that make management or TI recommendations for COVID-19 using the AGREE II instrument.
The proposed systematic review will identify CPGs for TI use and/or the management of COVID-19. The MEDLINE, EMBASE, CINAHL, and Web of Science databases, as well as the Guidelines International Network, National Institute for Health and Clinical Excellence, Scottish Intercollegiate Guidelines Network, and the World Health Organization websites, will be searched from December 2019 onwards. The primary outcome of this study is the assessed quality of the CPGs. The quality of eligible CPGs will be assessed using the Appraisal of Guidelines, Research and Evaluation II (AGREE II) instrument. Descriptive statistics will be used to quantify the quality of the CPGs. The secondary outcomes of this study are the types of management and/or TI recommendations made. Inconsistent and duplicate TI and/or management recommendations made between CPGs will be compared across guidelines. To summarize and explain the findings related to the included CPGs, a narrative synthesis will also be provided.
The results of this study will be of utmost importance to enhancing clinical decision-making among healthcare providers caring for patients with COVID-19. Moreover, the results of this study will be relevant to guideline developers in the creation of CPGs or improvement of existing ones, researchers who want to identify gaps in knowledge, and policy-makers looking to encourage and endorse the adoption of CPGs into clinical practice. The results of this review will be published in a peer-reviewed journal and presented at conferences.
International Prospective Register for Systematic Reviews (PROSPERO)- CRD42020219944.
2019 年 12 月,一种新型冠状病毒,即严重急性呼吸综合征冠状病毒 2 被确定为急性呼吸道疾病,即 2019 年冠状病毒病(COVID-19)的病因。鉴于缺乏经过验证的治疗方法,迫切需要对 COVID-19 进行高质量的管理。临床实践指南(CPGs)是医疗保健提供者可能用来提高患者护理质量的一种工具。因此,他们需要能够获得高质量的循证 CPG,以便他们能够根据管理和使用治疗干预措施(TI)的决定COVID-19。本研究的目的是使用 AGREE II 工具评估针对 COVID-19 制定管理或 TI 建议的 CPG 的质量。
拟议的系统评价将确定用于 TI 使用和/或 COVID-19 管理的 CPG。将从 2019 年 12 月起搜索 MEDLINE、EMBASE、CINAHL 和 Web of Science 数据库,以及指南国际网络、英国国家卫生与临床优化研究所、苏格兰校际指南网络和世界卫生组织网站。本研究的主要结果是评估 CPG 的质量。合格 CPG 的质量将使用评估指南、研究和评估 II(AGREE II)工具进行评估。将使用描述性统计来量化 CPG 的质量。本研究的次要结果是管理和/或 TI 建议的类型。将对 CPG 之间不一致和重复的 TI 和/或管理建议进行比较。为了总结和解释与纳入的 CPG 相关的发现,还将提供叙述性综合。
这项研究的结果对于提高护理 COVID-19 患者的医疗保健提供者的临床决策至关重要。此外,这项研究的结果对于指南制定者制定 CPG 或改进现有 CPG、希望确定知识差距的研究人员以及希望鼓励和支持将 CPG 纳入临床实践的政策制定者都具有重要意义。该综述的结果将发表在同行评议的期刊上,并在会议上发表。
国际前瞻性系统评价注册库(PROSPERO)- CRD42020219944。